We found that the reduction in MEF2D methylation caused by KDM1A dramatically increased its binding to the PD-L1 promoter and elevated PD-L1 expression in HCC, as confirmed by the use of the KDM1A inhibitor ORY-001. The gene discussed is KDM1A; the disease is hepatocellular carcinoma.